Tempero Bio is a clinical-stage biopharmaceutical company developing treatments for Substance Use Disorders and related disorders. Tempero Bio is a portfolio company of Aditum Bio, the biotech investment firm co-founded in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for BioMedical Research (NIBR) Dr. Mark Fishman.
Our lead therapeutic drug candidate, TMP-301, is a potent, orally available, metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM) that is being investigated for the treatment of Substance Use Disorders, including Cocaine Use Disorder (CUD) and Alcohol Use Disorder (AUD). Additional discovery is also underway on the potential of TMP-301 to treat other addictive disorders, such as Methamphetamine Use Disorder (MUD) and Polysubstance Use Disorder (PUD).
Company Details
- Employees
- 6
- Founded
- -
- Address
- 1111 Broadway,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.temperobio.com
- HQ
- Oakland, California
Tempero Bio Questions
Tempero Bio's website is http://www.temperobio.com
Tempero Bio's LinkedIn profile is https://www.linkedin.com/company/tempero-bio-inc
Tempero Bio has
6 employees.
View email and phone details for 6
employees at Tempero Bio.
Tempero Bio's industry is
Biotechnology Research
Tempero Bio's top competitors are
Aditum Bio,
Uniqure,
Yoda Therapeutics Inc.,
Ampersand Biomedicines,
Sineugene Therapeutics,
Hillstar Bio,
Augustine Therapeutics,
Character Biosciences,
Tribune Therapeutics,
Epicrispr Biotechnologies.
Tempero Bio's categories are Biotechnology Research
Tempero Bio's founding year is 2020
